Background

Factor X deficiency is a rare inherited bleeding disorder characterized by a deficiency or malfunction of coagulation Factor X, also known as the Stuart-Prower factor. This essential clotting protein is responsible for initiating the coagulation cascade, which eventually leads to the formation of stable blood clots.

The deficiency of Factor X disrupts the normal clotting process, resulting in prolonged bleeding and an increased risk of hemorrhages, both externally and internally. Symptoms might vary widely depending on the severity of the deficiency, ranging from mild bleeding tendencies to severe, life-threatening bleeding episodes.

Factor X deficiency is diagnosed through specialized blood tests, and treatment involves replacing the missing clotting factor through infusions or using medications to promote clotting. While rare, the condition requires careful management and monitoring to prevent complications associated with bleeding episodes. 

Epidemiology

Factor X deficiency, also known as Stuart-Prower factor deficiency, is a infrequent bleeding disorder caused by the deficiency of clotting factor X, a vitamin K-dependent serine protease involved in thrombus formation.  

Prevalence and Incidence:  

The prevalence of Factor X deficiency is estimated to be around 1 per million individuals globally. The estimated incidence of this autosomal recessive disorder ranges from 1 in 500,000 to 1 in a million. Severe forms of congenital Factor X deficiency, caused by mutations in the F10 gene, have a prevalence of approximately 1 in 1,000,000. 

Affected Populations:  

Factor X deficiency affects both males and females. The severity of the disorder can vary, and symptoms can start at any age, but severe cases are more evident in childhood.  

Women with Factor X deficiency may experience menorrhagia (excessive menstrual bleeding) and are at an increased risk of bleeding during childbirth, with a higher risk of miscarriage. Newborns with inherited Factor X deficiency may exhibit excessive bleeding at the umbilical stump. 

Factor X deficiency does not show any racial or ethnic bias, and it affects both males and females equally. 

Anatomy

Pathophysiology

Factor X deficiency, also known as Stuart-Prower factor deficiency, is a bleeding disorder caused by a deficiency or dysfunction of coagulation Factor X. Factor X is a crucial protein in the coagulation cascade, which plays a central role in the formation of blood clots to stop bleeding. 

The coagulation cascade is a complex series of interactions between different clotting factors, leading to the activation of Factor X into its active form, Factor Xa. Factor Xa then works in conjunction with other clotting factors to convert prothrombin into thrombin, a key enzyme responsible for converting fibrinogen into fibrin. Fibrin is a fibrous protein that forms a meshwork, providing the structural framework for the blood clot. 

In Factor X deficiency, the insufficient amount or malfunctioning of Factor X leads to a compromised coagulation process. As a result, the conversion of prothrombin to thrombin is impaired, leading to inadequate fibrin formation and clot stabilization. Consequently, affected individuals experience difficulties forming stable blood clots, leading to prolonged bleeding and an increased risk of internal and external bleeding episodes. 

Factor X deficiency is typically an inherited disorder caused by the mutations in the F10 gene, which encodes Factor X. These mutations can result in reduced synthesis of Factor X, impaired function, or unstable protein structures. Inheritance is usually autosomal recessive, meaning an individual must inherit two defective copies of the F10 gene, one from each parent, to develop the disorder. 

The severity of Factor X deficiency can vary depending on the level of Factor X activity in the blood. Mild cases may go unnoticed until situations that increase clotting demands, such as trauma or surgery, trigger abnormal bleeding. Severe cases can result in spontaneous, severe bleeding episodes that require immediate medical attention. 

Etiology

Factor X deficiency, also known as Stuart-Prower factor deficiency, has a genetic etiology and is primarily caused by mutations in the F10 gene. The F10 gene is located on chromosome 13 and encodes for Factor X, an essential protein involved in the coagulation cascade. 

The inheritance pattern of Factor X deficiency is typically autosomal recessive. This means an individual must inherit two copies of the defective F10 gene, one from each parent, to develop the disorder. If both parents are carriers of the mutated F10 gene (heterozygous carriers), there is a 25% chance that their child will have Factor X deficiency. 

The mutations in the F10 gene can lead to various types of Factor X deficiency, including: 

• Type I deficiency: This type is characterized by reduced production of Factor X, resulting in lower protein levels in the blood. 
• Type II deficiency: In this type, a functional abnormality in the produced Factor X leads to impaired clotting activity despite normal or near-normal protein levels. 
• Type III deficiency: This is the most severe form of Factor X deficiency, where both production and function of Factor X are affected, resulting in extremely low or non-detectable protein levels. 

In some cases, acquired Factor X deficiency can occur due to other medical conditions, such as liver disease, vitamin K deficiency, or the presence of Factor X inhibitors (antibodies that neutralize the activity of Factor X). However, acquired Factor X deficiency is relatively rare compared to the inherited form. 

Genetics

Prognostic Factors

Like many other bleeding disorders, the prognosis of Factor X deficiency can vary depending on several factors. These prognostic factors influence the severity of the condition, the frequency and severity of the bleeding episodes, and the overall quality of life for affected individuals.  

• Type and Severity of Factor X Deficiency: The type of Factor X deficiency (Type I, Type II, or Type III) and the severity of the deficiency play a significant role in determining the prognosis. Individuals with Type III deficiency, where both production and function of Factor X are severely affected, generally experience more frequent and severe bleeding episodes than those with Type I or Type II deficiency. 
• Factor X Activity Levels: Factor X activity in the blood is crucial for predicting the risk of bleeding episodes. Lower levels of Factor X are associated with a higher likelihood of bleeding problems. Individuals with very low or undetectable Factor X levels are more susceptible to spontaneous bleeding and may require more aggressive management. 
• Age of Onset and Diagnosis: Early diagnosis and intervention can improve outcomes. If Factor X deficiency is diagnosed early, appropriate preventive measures can be implemented, diminishing the risk of severe bleeding episodes and long-term complications. 
• Inhibitors: The presence of inhibitors (antibodies that neutralize Factor X activity) can complicate the management of Factor X deficiency. Inhibitors can interfere with replacement therapy, making it less effective and increasing the risk of bleeding. 
• Access to Treatment and Management: Availability of appropriate treatment, access to specialized care, and adherence to treatment plans significantly impact the prognosis. Regular monitoring and prompt management of bleeding episodes are essential for better outcomes. 
• Underlying Health Conditions: Underlying health issues like liver disease or vitamin K deficiency can worsen Factor X deficiency and affect prognosis. Managing these underlying conditions is crucial to improving the overall outcome. 
• Lifestyle and Activity Level: Taking precautions to avoid injuries and engaging in low-risk activities can reduce the occurrence of bleeding episodes. Maintaining a healthy lifestyle and avoiding activities with a high risk of trauma can positively impact the prognosis. 
• Pregnancy and Surgery: For women with Factor X deficiency, pregnancy, and childbirth can present additional challenges due to the increased risk of bleeding. Proper management and close monitoring during pregnancy and surgery are essential to ensure positive outcomes. 

Clinical History

Age Group: Factor X deficiency is typically present from birth, as it is an inherited genetic disorder. However, the symptoms may not be apparent in mild cases until later in life or triggered by specific events like trauma or surgery. Severe cases are often diagnosed during infancy or childhood due to spontaneous bleeding episodes. Therefore, the age group of presentation can range from infancy to adulthood. 

Physical Examination

The physical examination of individuals with Factor X deficiency is essential for assessing the severity of the bleeding disorder and identifying any bleeding manifestations.  

• Bruising and Petechiae: The healthcare provider will look for signs of bruising (ecchymosis) or small red or purple spots on the skin (petechiae). These can be indicative of bleeding under the skin due to impaired clotting. 
• Joint and Muscle Bleeding: The examination may involve assessing signs of bleeding into joints (hemarthrosis) and muscles (hematoma). Swelling, warmth, tenderness, and limited range of motion in joints may be observed in individuals with joint bleeding. 
• Mucous Membrane Bleeding: The provider will examine the mucous membranes, like the gums, nose, and gastrointestinal tract, for signs of bleeding. This can include gum bleeding, nosebleeds (epistaxis), or gastrointestinal bleeding, which may present as black, tarry stools (melena) or blood in the vomit (hematemesis). 
• Bleeding After Injuries or Procedures: The examiner will inquire about any history of recent injuries, surgeries, or dental procedures, as these can trigger bleeding episodes in individuals with Factor X deficiency. 
• Menstrual History: For female patients, the healthcare provider may inquire about menstrual history and assess for excessive or prolonged menstrual bleeding (menorrhagia). 
• Family History: Since Factor X deficiency is often inherited, the examiner will ask about the family history of bleeding disorders or consanguinity (blood-related parents). 
• Joint Evaluation: In cases of suspected joint bleeding, the provider may perform a joint evaluation to assess for swelling, warmth, and tenderness in affected joints. 
• Neurological Examination: In severe cases or after significant bleeding events, a neurological examination may be performed to evaluate signs of intracranial bleeding, such as headaches, altered mental status, or neurological deficits. 
• Laboratory Tests: Confirmation of Factor X deficiency requires laboratory tests to measure Factor X activity and rule out other bleeding disorders. 

Age group

Associated comorbidity

No specific comorbidities are uniquely associated with Factor X deficiency. However, certain factors or activities can trigger bleeding episodes or exacerbate the condition.

These may include trauma, surgery, dental procedures, menstruation in women, or any situation that requires increased clotting. In individuals with Factor X deficiency, these events can lead to prolonged bleeding, bruising, or joint bleeding. 

Associated activity

Acuity of presentation

The acuity of the presentation may vary depending on the severity of Factor X deficiency. In mild cases with relatively higher Factor X levels, bleeding symptoms may be subtle or infrequent. Mild cases may go undiagnosed until a significant bleeding event occurs or until triggered by surgeries or injuries. 

Individuals may experience more frequent and prolonged bleeding episodes in moderate cases, especially after injuries or medical procedures. These bleeding episodes can range from mild to moderate in severity and may involve prolonged bleeding from cuts or dental extractions. 

In severe cases, individuals may have life-threatening bleeding episodes, both externally and internally. They may experience spontaneous bleeding into joints or muscles without any apparent cause. Even minor injuries can lead to prolonged bleeding or severe blood loss in some severe cases. 

Differential Diagnoses

• Other Inherited Bleeding Disorders: Various other inherited bleeding disorders, such as hemophilia A (Factor VIII deficiency), hemophilia B (Factor IX deficiency), and von Willebrand disease, can present with similar bleeding symptoms. These conditions also affect the coagulation cascade’s specific clotting factors or proteins. 
• Acquired Coagulation Disorders: Certain medical conditions, such as liver disease or vitamin K deficiency, can lead to acquired coagulation disorders. Liver disease can affect the synthesis of clotting factors, including Factor X, while vitamin K deficiency can impair the activation of clotting factors. 
• Platelet Disorders: Some platelet disorders, such as idiopathic thrombocytopenic purpura (ITP) or platelet function disorders, can cause bleeding symptoms similar to those seen in Factor X deficiency. Platelet disorders result in abnormal platelet function or decreased platelet counts, leading to impaired blood clotting. 
• Vascular Abnormalities: Some vascular abnormalities, like hereditary hemorrhagic telangiectasia (HHT), can lead to frequent nosebleeds and other mucosal bleeding, which may be mistaken for bleeding due to coagulation factor deficiencies. 
• Medication-induced Bleeding: Certain medications, such as anticoagulants (e.g., warfarin, heparin) or antiplatelet agents (e.g., aspirin, clopidogrel), can cause bleeding complications. 
• Disseminated Intravascular Coagulation (DIC): DIC is a complex, acquired disorder characterized by excessive clotting and bleeding due to various underlying conditions such as infections, severe trauma, or certain cancers. 
• Liver Disease: Aside from affecting clotting factor synthesis, liver dysfunction can also lead to other bleeding-related issues due to impaired production of other proteins involved in hemostasis. 
• Von Willebrand Disease (VWD): VWD is the most common inherited bleeding disorder and can cause prolonged bleeding episodes similar to those seen in some cases of Factor X deficiency. 

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

The treatment paradigm of Factor X deficiency aims to prevent and manage bleeding episodes by replacing the deficient clotting factor and providing supportive care.  

• Factor X Replacement Therapy: The cornerstone of treatment involves administering Factor X replacement to increase the level of the deficient clotting factor in the blood. Factor X concentrates derived from human plasma or produced through recombinant technology are used for this purpose. The frequency and dosage of replacement therapy depend on the severity of the deficiency and the clinical situation. Replacement therapy may be administered as needed for mild cases or minor bleeding episodes. Regular prophylactic infusions may be recommended for more severe cases, surgeries, or other high-risk situations to maintain adequate Factor X levels. 
• Prophylaxis: In individuals with severe Factor X deficiency and a history of frequent or severe bleeding episodes, prophylactic factor replacement therapy may be prescribed to prevent bleeding. Prophylaxis involves regular infusions of Factor X concentrates to maintain a certain level of the clotting factor in the blood, reducing the risk of spontaneous bleeding. 
• Surgical and Dental Management: Before surgeries or dental procedures, individuals with Factor X deficiency should receive Factor X replacement therapy to maintain adequate clotting factor levels during and after the procedure. This is essential to minimize bleeding risks and promote proper wound healing. 
• Supportive Care: Besides Factor X replacement, supportive care measures are employed to manage bleeding episodes effectively. These may include applying pressure to wounds, elevating injured limbs, and using ice packs to reduce swelling and bleeding. 
• Management of Bleeding Episodes: Prompt treatment is essential in cases of bleeding episodes. Based on the severity of the bleeding, additional Factor X replacement therapy may be required, along with supportive care measures. For severe bleeds, hospitalization, and close monitoring may be necessary. 
• Genetic Counseling: Genetic counseling is crucial for individuals with Factor X deficiency and their family members to understand the inheritance pattern and assess the risk of passing the condition to the future generations. 
• Avoiding Triggering Factors: Individuals with Factor X deficiency should be educated about avoiding activities or situations that could lead to bleeding, such as contact sports or certain medications that can increase bleeding risks. 
• Monitoring and Follow-up: Regular monitoring of Factor X levels and clinical assessment is essential to adjust treatment regimens and ensure adequate management. 

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

use-of-the-non-pharmacological-therapy-for-modifying-the-environment

Modifying the environment for individuals with Factor X deficiency involves making certain lifestyle adjustments and taking precautions to minimize the risk of bleeding episodes. While this cannot replace medical treatment, it can significantly reduce bleeding events and improve overall quality of life.  

• Avoiding High-Risk Activities: Avoiding high-risk activities that increase the likelihood of injuries or trauma should be minimized. Activities like contact sports, extreme sports, or activities with a high risk of falls or accidents should be avoided or approached cautiously. 
• Safe Exercise and Physical Activity: Encourage participation in low-impact and safe exercise activities that promote overall health without increasing the risk of injury. Swimming, walking, and yoga are low-risk physical activities that help maintain fitness without undue bleeding risks. 
• Safety Measures at Home: Ensuring a safe living environment is crucial for individuals with Factor X deficiency. Installing safety rails, removing sharp objects or potential hazards, and maintaining clutter-free spaces can help prevent accidental injuries at home. 
• Preventing Falls: Reducing the risk of falls is essential to prevent bleeding events. Installing non-slip mats in the bathroom, using handrails on stairs, and wearing appropriate footwear can prevent falls. 
• Dental Care: oral hygiene and regular dental check-ups are vital to prevent dental issues that can trigger bleeding in the mouth. Dental procedures should be carefully planned, and Factor X replacement therapy should be administered before dental work. 
• Avoiding Certain Medications: Medications like nonsteroidal anti-inflammatory drugs (NSAIDs) or anticoagulants can increase bleeding risks. Individuals with Factor X deficiency should consult their healthcare provider before taking new medications and avoid those that can affect blood clotting. 
• Menstrual Management: Women with Factor X deficiency should work with their healthcare provider to manage menstruation effectively and minimize bleeding complications. 
• Travel Precautions: Individuals should carry their medical records, including information about Factor X deficiency and their treatment plan. Planning for emergency medical care at their travel destination is essential. 
• Education and Communication: Ensuring that family members, friends, teachers, and colleagues are aware of the condition and its implications can be beneficial in providing support and understanding. 

Use of Plasma-derived factor X concentrate for treating Factor X Deficiency

Treatment for factor X deficiency typically involves replacing the missing or defective factor X with a plasma-derived factor X concentrate.  

• Plasma-Derived Factor X Concentrate: Plasma-derived factor X concentrate is a product made from human plasma that contains concentrated factor X. It is obtained through a process called fractionation, where plasma is collected from multiple donors and processed to isolate and purify factor X. 
• Administration: Factor X concentrate is administered intravenously (IV) into the bloodstream. The dose and the frequency of administration based on severity of the factor X deficiency and the presence of bleeding episodes. 

• Treatment of Bleeding Episodes: Factor X concentrate is used to treat bleeding episodes in individuals with factor X deficiency. It helps to restore the clotting ability of the blood, allowing for the formation of stable blood clots to stop bleeding. 
• Prophylactic Treatment: In some cases, especially for individuals with severe factor X deficiency or a history of frequent bleeding episodes, prophylactic (preventive) treatment may be recommended. Prophylactic treatment involves regular infusions of factor X concentrate to maintain adequate levels of factor X and prevent bleeding episodes. 
• Monitoring and Dosing: Regular monitoring of factor X levels is essential to ensure appropriate dosing and efficacy of treatment. Depending on the individual’s response to treatment and the frequency of bleeding episodes, the dosage and frequency of factor X concentrate administration may be adjusted. 
• Managing Surgical Procedures: Before any surgical or dental procedures, factor X concentrate may be given to raise factor X levels and minimize the risk of excessive bleeding. 
• Management of Complications: While factor X concentrate is the mainstay of treatment, additional measures may be taken to manage complications related to factor X deficiency, such as the use of supportive therapies and treatments to address joint damage resulting from repeated bleeding. 

Use of 3-factor or 4-factor prothrombin complex concentrate for treating Factor X Deficiency

In the treatment of Factor X deficiency, prothrombin complex concentrate (PCC) is commonly used to replace the deficient Factor X. PCC contains a combination of clotting factors, including Factor X, and is available as either 3-factor or 4-factor PCC. Both types of PCC can be used to manage bleeding episodes and, in some cases, for prophylactic treatment. 

• 3-Factor Prothrombin Complex Concentrate: 3-factor PCC contains concentrated forms of three clotting factors: Factor II (prothrombin), Factor IX, and Factor X. It is used to treat bleeding episodes and can be effective in achieving hemostasis in individuals with Factor X deficiency. However, it lacks Factor VII, which is an essential factor in the extrinsic pathway of the coagulation cascade. As a result, it may not be as effective as 4-factor PCC in certain situations. 
• 4-Factor Prothrombin Complex Concentrate: 4-factor PCC contains concentrated forms of four clotting factors: Factor II, Factor VII, Factor IX, and Factor X. It is sometimes referred to as “four-factor PCC” or “activated PCC” because it contains Factor VII, which plays an important role in the initiation of the coagulation cascade. 4-factor PCC is generally considered more effective than 3-factor PCC, especially in cases where Factor VII activity is also reduced. 

The choice between 3-factor and 4-factor PCC depends on several factors, including the availability of these products in a specific healthcare setting, the individual’s bleeding pattern and severity, and the response to previous treatments.

For patients with severe Factor X deficiency or a history of frequent and severe bleeding episodes, 4-factor PCC may be preferred due to its more comprehensive coagulation factor content. 

Use of Fresh Frozen Plasma (solvent or detergent) for treating Factor X Deficiency

Fresh Frozen Plasma (FFP) and solvent/detergent (S/D) treatment are two different treatment approaches used for managing bleeding episodes in individuals with Factor X deficiency.  

• Fresh Frozen Plasma (FFP): FFP is a blood product that contains a variety of clotting factors, including Factor X. It is obtained by separating and freezing the liquid portion of the blood (plasma) from whole blood donations. FFP is often used as a source of multiple clotting factors to correct coagulation disorders, including Factor X deficiency. 
• Solvent/Detergent (S/D) Treatment: S/D treatment is a method of virus inactivation that can be applied to plasma-derived products, including prothrombin complex concentrates (PCCs), to reduce the risk of viral transmission. The process involves treating plasma with a solvent and detergent to inactivate enveloped viruses. 

PCCs treated with S/D have been used in the treatment of bleeding disorders, including Factor X deficiency. These S/D-treated PCCs can provide concentrated levels of clotting factors, including Factor X, in a smaller volume compared to FFP. S/D treatment helps enhance the safety of plasma-derived products by reducing the risk of transmitting certain viruses, such as HIV, hepatitis B, and hepatitis C. 

Use of Supplemental vitamin K for treating Factor X Deficiency

Factor X deficiency is a infrequent bleeding disorder in which the blood lacks sufficient levels of Factor X, a critical clotting factor required for normal blood coagulation. Vitamin K is important for the synthesis of various clotting factors, including Factor X, in the liver.  

Supplemental vitamin K is not typically used as a treatment for Factor X deficiency because the underlying cause is related to a genetic deficiency of the Factor X protein. Unlike some other bleeding disorders (such as certain types of hemophilia), where the body may produce insufficient clotting factors due to a vitamin K deficiency, Factor X deficiency is a result of a specific genetic mutation affecting Factor X production. 

The treatment of Factor X deficiency usually involves managing bleeding episodes with clotting factor replacement therapy, similar to other clotting factor deficiencies. This can be in the form of fresh frozen plasma (FFP), prothrombin complex concentrates (PCC), or recombinant Factor X concentrate, depending on the severity and individual needs of the patient. 

Supplemental vitamin K is more commonly used in treating vitamin K deficiency or certain liver diseases that impair the synthesis of clotting factors, not specifically for Factor X deficiency.  

Factor X deficiency is a infrequent bleeding disorder in which the blood lacks sufficient levels of Factor X, a critical clotting factor required for normal blood coagulation. Vitamin K is important for the synthesis of various clotting factors, including Factor X, in the liver. Supplemental vitamin K is not typically used as a treatment for Factor X deficiency because the underlying cause is related to a genetic deficiency of the Factor X protein. Unlike some other bleeding disorders (such as certain types of hemophilia), where the body may produce insufficient clotting factors due to a vitamin K deficiency, Factor X deficiency is a result of a specific genetic mutation affecting Factor X production. The treatment of Factor X deficiency usually involves managing bleeding episodes with clotting factor replacement therapy, similar to other clotting factor deficiencies. This can be in the form of fresh frozen plasma (FFP), prothrombin complex concentrates (PCC), or recombinant Factor X concentrate, depending on the severity and individual needs of the patient. Supplemental vitamin K is more commonly used in treating vitamin K deficiency or certain liver diseases that impair the synthesis of clotting factors, not specifically for Factor X deficiency

Factor X deficiency is a infrequent bleeding disorder in which the blood lacks sufficient levels of Factor X, a critical clotting factor required for normal blood coagulation. Vitamin K is important for the synthesis of various clotting factors, including Factor X, in the liver.  

Supplemental vitamin K is not typically used as a treatment for Factor X deficiency because the underlying cause is related to a genetic deficiency of the Factor X protein. Unlike some other bleeding disorders (such as certain types of hemophilia), where the body may produce insufficient clotting factors due to a vitamin K deficiency, Factor X deficiency is a result of a specific genetic mutation affecting Factor X production. 

The treatment of Factor X deficiency usually involves managing bleeding episodes with clotting factor replacement therapy, similar to other clotting factor deficiencies. This can be in the form of fresh frozen plasma (FFP), prothrombin complex concentrates (PCC), or recombinant Factor X concentrate, depending on the severity and individual needs of the patient. 

Supplemental vitamin K is more commonly used in treating vitamin K deficiency or certain liver diseases that impair the synthesis of clotting factors, not specifically for Factor X deficiency.  

factor-x-deficiency-is-a-infrequent-bleeding-disorder-in-which-the-blood-lacks-sufficient-levels-of-factor-x-a-critical-clotting-factor-required-for-normal-blood-coagulation-vitamin-k-is-important-f

Factor X deficiency is a infrequent bleeding disorder in which the blood lacks sufficient levels of Factor X, a critical clotting factor required for normal blood coagulation. Vitamin K is important for the synthesis of various clotting factors, including Factor X, in the liver.  

Supplemental vitamin K is not typically used as a treatment for Factor X deficiency because the underlying cause is related to a genetic deficiency of the Factor X protein. Unlike some other bleeding disorders (such as certain types of hemophilia), where the body may produce insufficient clotting factors due to a vitamin K deficiency, Factor X deficiency is a result of a specific genetic mutation affecting Factor X production. 

The treatment of Factor X deficiency usually involves managing bleeding episodes with clotting factor replacement therapy, similar to other clotting factor deficiencies. This can be in the form of fresh frozen plasma (FFP), prothrombin complex concentrates (PCC), or recombinant Factor X concentrate, depending on the severity and individual needs of the patient. 

Supplemental vitamin K is more commonly used in treating vitamin K deficiency or certain liver diseases that impair the synthesis of clotting factors, not specifically for Factor X deficiency.  

Medication

Future Trends

Media Gallary

References

Diagnosis and treatment of inherited factor X deficiency – PubMed (nih.gov) 

Diagnosis and treatment of inherited factor X deficiency – BROWN – 2008 – Haemophilia – Wiley Online Library 

Factor X deficiency Information | Mount Sinai – New York 

Orphanet: Congenital factor X deficiency 

Factor X Deficiency: Symptoms, Causes, Treatment, and More (healthline.com) 

Factor X | National Hemophilia Foundation 

Factor X deficiency: MedlinePlus Genetics